Pharming Group N.V.

Share Issue/Capital Change • Jun 15, 2012

PHARMING UPDATES ON STUDY 1310 AND SHARES IN ISSUE

Leiden, The Netherlands, June 15, 2012. Biotech company Pharming Group NV ("Pharming" or "the Company") (NYSE Euronext: PHARM) today provides a short update from its press release dated June 12, 2012.

Study 1310, the Phase III clinical study with RUCONEST® that is intended to support the submission of a Biologics License Application (BLA) to the US FDA, continues to recruit with additional patients enrolled this week. Currently 70 of the 75 patients required for the completion of Study 1310 have been treated.

In addition, as announced in Pharming's press release dated December 23, 2011; under the €8.4 million private bond, which has now been redeemed in shares in full, a top- up payment in shares caused by the drop in share price over the last month has become due. Therefore 18,330,106 shares will be issued to the bondholders under the terms and conditions of the bond.

As of today, the number of outstanding shares has increased from 670,662,545 to 688,992,651.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (OMX: SOBI). RUCONEST® is partnered with Santarus, Inc (NASDAQ: SNTS) in North America where the drug is undergoing Phase III clinical development. The product is also being evaluated for follow-on indications in the areas of transplantation and reperfusion injury. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products. A feasibility study, using the validated transgenic rabbit platform, aimed at the development of recombinant Factor VIII for the treatment of Haemophilia A is underway with partner, Renova Life, Inc. Additional information is available on the Pharming website, www.pharming.com. To download the Pharming Group Investor Relations App, click here.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact

Pharming Sijmen de Vries, CEO: T: +31 (0)71 524 7400 Karl Keegan, CFO: T: +31 (0)71 524 7400

FTI Consulting Julia Phillips, T: +44 (0)207 269 7187 John Dineen, T: +44 (0)207 269 7193